交易 Arvinas Inc - ARVN CFD

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

最新股票文章

中國的經濟危機比想像中還嚴重?
中國的經濟危機比想像中還嚴重?
中國經濟正面臨嚴峻困境,而這張圖清楚說明了原因。圖表顯示中國的房地產投資、新開工項目以及房屋銷售的表現。
16:41, 27 7月 2025
特斯拉財報不及預期後的交易動向
特斯拉財報不及預期後的交易動向
第二季財報盈餘與營收皆未達預期,股價在盤後交易下跌,執行長馬斯克警告可能將面臨「幾個艱難的季度」
20:07, 24 7月 2025
為何麥可·貝利(Michael Burry)剛清倉所有股票?
為何麥可·貝瑞(Michael Burry)剛剛清倉所有股票
麥可·貝瑞剛剛拋售了超過7,000萬美元的股票,清空了他的整個投資組合,只保留一支股票,並對這家公司加碼,而其他投資人則紛紛出逃。
18:37, 22 7月 2025
道瓊交易觀察
道瓊交易觀察:財報季成為市場焦點
上週,美國主要股指表現分化,其中道瓊工業指數表現相對落後於科技權重較高的指數,但從技術面來看,道瓊仍維持多頭趨勢,並持續受到CoT(持倉報告)投機者的淨多頭偏好所支撐。
17:26, 21 7月 2025